
TAE Life Sciences’ Novel Boron Drugs for BNCT Show Enhanced Tumor Suppression with Immunotherapy in Preclinical Models
TAE Life Sciences’ Next-Generation Boron Drugs Show Promising Synergy with Immunotherapy in Preclinical BNCT Studies TAE Life Sciences (TLS), a leading biotechnology company focused on next-generation cancer therapies, today announced compelling preclinical results from its ongoing collaboration with Kyoto University.…












